Skip to main content

Table 1 Clinical characteristics and CGMS parameters

From: Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes

Variables All (n = 57)
Age (years) 65 ± 12
Male (%) 78.9
Body mass index (kg/m2) 24.2 ± 4.1
STEMI (%) 77.2
Multivessel disease (%) 35.1
Culprit vessel
 Left anterior descending artery (%) 52.6
 Left circumflex coronary artery (%) 14.0
 Right coronary artery (%) 33.3
Current smoking (%) 54.4
Hypertension (%) 61.4
Diabetes mellitus (%) 49.1
Lipid parameters at admission
 Total cholesterol (mg/dl) 201 ± 37
 LDL-C (mg/dl) 128 ± 36
 HDL-C (mg/dl) 46 ± 12
 Triglycerides (mg/dl) 129 ± 96
eGFR at admission (ml/min/1.73 m2) 75.2 ± 18.2
Urinary L-FABP (μg/g creatinine) 20.3 ± 58.0
hs-CRP at 7 days after admission (mg/dl) 1.56 ± 1.72
Medications before admission
 Statin (%) 21.1
 ACEI/ARB (%) 21.1
 Oral anti-diabetic drugs (%) 17.5
Conventional glucose indicators
 HbA1c at admission (%) 6.1 ± 1.0
 FPGa (mg/dl) 109 ± 17
 HOMA-IRa 2.1 ± 1.4
CGMS parametersa
 Maximum blood glucose (mg/dl) 184 ± 48
 Minimum blood glucose (mg/dl) 90 ± 21
 Mean blood glucose (mg/dl) 126 ± 27
 SD around mean blood glucose (mg/dl) 22 ± 12
 MAGE (blood glucose variability) (mg/dl) 48 ± 26
 Hyperglycemia ≥200 mg/dl (%) 29.8
 Hypoglycemia <60 mg/dl (%) 7.0
  1. ACEI/ARB angiotensin-converting enzyme inhibitor and/or angiotensin II receptor blocker, CGMS continuous glucose monitoring system, eGFR estimated glomerular filtration ratio, FPG fasting plasma glucose, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostasis model assessment of insulin resistance, LDL-C low-density lipoprotein cholesterol, MAGE mean amplitude of glucose excursion, STEMI ST-segment elevation myocardial infarction, L-FABP liver-type fatty acid-binding protein (in the first morning urine on the day after admission)
  2. aMeasured in a stable condition during hospital admission